| Literature DB >> 35406468 |
Mustafa Zelal Muallem1, Jalid Sehouli1, Andrea Miranda1, Helmut Plett1, Ahmad Sayasneh2, Yasser Diab3, Jumana Muallem1, Imad Hatoum1.
Abstract
(1) Background: plastic reconstruction in vulvar surgery can lead to a better treatment outcome than primary closure. This study aims to compare the preoperative parameters (co-morbidities and tumor size) and postoperative results (tumor free margins and wound healing) between the primary closure and reconstructive surgery after vulvar cancer surgery; (2)Entities:
Keywords: flap; primary closure; reconstructive surgery; vulvar cancer; vulvectomy; wound healing
Year: 2022 PMID: 35406468 PMCID: PMC8997096 DOI: 10.3390/cancers14071695
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639
Figure 1Pelvic reconstruction following a posterior exenteration with resection of Anus, posterior vaginal wall and vulva using the corpus uteri as a muscular flap: (a) the vulvar tumor with infiltration of anal sphincter; (b) intraoperative photo of adapting the corpus uteri flap to the defect edges after the demolitive surgery; (c) Magnetic resonance imaging of the corpus uteri flap two weeks after surgery.
Figure 2Perfusion assessment with fluorescence imaging system after injecting indocyanine green in (a) Overlay mode; (b) SPY fluorescence mode; (c) Color segmented fluorescence mode and (d) White light one week after surgery. This figure showed the very poor flap perfusion indicated with ICG-imaging study intraoperatively and the necrotic flap one week later.
Patient’s and tumor’s characteristics.
| Characteristic | All Patients | Reconstructive Surgery (RS) | Primary Closure (PC) | ||
|---|---|---|---|---|---|
| Age at first diagnosis, median (range) years | 70 (28–91) | 71 (28–86) | 67 (35–91) | 0.604 | |
| Charlson’s comorbidity score | 0 | 109 (61.6%) | 84 (66.7%) | 25 (49%) | 0.043 |
| 1–3 | 49 (27.7%) | 32 (25.4%) | 17 (33.3%) | ||
| 4–6 | 17 (9.6%) | 9 (7.1%) | 8 (15.7%) | ||
| ≥7 | 2 (1.1%) | 1 (0.8%) | 1 (2%) | ||
| American Society of Anesthesiologists | ASA 1 | 19 (10.7%) | 12 (9.5%) | 7 (13.7%) | 0.582 |
| ASA 2 | 111 (62.7%) | 83 (65.9%) | 28 (54.9%) | ||
| ASA 3 | 47 (26.6%) | 31 (24.6%) | 16 (31.4%) | ||
| Histology | Keratinizing squamous | 138 (78%) | 97 (77%) | 41 (80.4%) | 0.768 |
| Non keratinizing squamous | 20 (11.3%) | 13 (10.3%) | 7 (13.7%) | ||
| Basaloid | 5 (2.8%) | 4 (3.2%) | 1 (2%) | ||
| Adenocarcinoma | 14 (7.9%) | 12 (9.5%) | 2 (3.9%) | ||
| Grading | G1 | 18 (10.2%) | 10 (7.9%) | 8 (15.7%) | |
| G2 | 117 (66.1%) | 81 (64.3%) | 36 (70.6%) | ||
| G3 | 32 (18.1%) | 26 (20.6%) | 6 (11.8%) | ||
| unknown | 10 (5.6%) | 9 (7.1%) | 1 (2%) | ||
| Tumor volume, median (range) mm | 31 (8–127) | 45 (20–127) | 23 (8–89) | 0.013 | |
Demolitive and reconstructive surgery characteristics.
| Characteristic | All Patients | Reconstructive Surgery (RS) | Primary Closure (PC) | ||
|---|---|---|---|---|---|
| Duration of surgery, median (range) minutes | 112 (20–335) | 134 (65–335) | 67 (20–280) | <0.001 | |
| Tumor free margins | 155 (87.8%) | 114 (90.4%) | 41 (80.4%) | 0.111 | |
| Wound healing disorders | 23 (13%) | 16 (12.7%) | 7 (13.7%) | 1.000 | |
| Type of demolitive surgery | Radical vulvectomy | 32 (18.1%) | 24 (19%) | 8 (15.7%) | 0.584 |
| Anterior vulvar resection | 78 (44.1%) | 66 (52.4%) | 12 (23.5%) | 0.001 | |
| Posterior vulvar resection | 22 (12.4%) | 17 (13.5%) | 5 (9.8%) | ||
| Hemivulvectomy left | 15 (8.5%) | 9 (7.1%) | 6 (11.8%) | ||
| Hemivulvectomy right | 12 (6.8%) | 6 (4.8%) | 6 (11.8%) | ||
| Wide excision | 14 (7.9%) | 0 (0%) | 14 (27.5%) | ||
| Exentration | 4 (2.3%) | 4 (3.2%) | 0 (0%) | ||
| Clitoris resection | 115 (65%) | 93 (73.8%) | 22 (43.1%) | 0.000 | |
| Partial or total resection of urethra | 37 (20.9%) | 32 (25.4%) | 5 (9.8%) | 0.035 | |
| Partial or total resection of anus | 14 (7.9%) | 14 (11.1%) | 0 (0%) | ||
| Sentinel lymph node staging only | 100 (56.5%) | 74 (58.7%) | 26 (50.1%) | ||
| Inguinal lymph node dissection | 73 (41.2%) | 52 (41.3%) | 21 (41.2%) | ||
| Type of reconstructive surgery | Fasciocutaneous V-Y flap | - | 54 (42.9%) | - | |
| Anterior pedicle labial flap | - | 8 (6.3%) | - | ||
| Posterior pedicle labial flap | - | 11 (8.7%) | - | ||
| Limberg flap | - | 9 (7.1%) | - | ||
| Myocutaneous flaps | - | 20 (15.9%) | - | ||
| Flap combination | - | 22 (17.5%) | - | ||
| Corpus uteri flap | - | 2 (1.6%) | - | ||
| FIGO | IA | 21 (11.9%) | 12 (9.5%) | 9 (17.6%) | |
| IB | 79 (44.6%) | 57 (45.2%) | 22 (43.1%) | ||
| II | 23 (13%) | 18 (14.3%) | 5 (9.8%) | ||
| IIIA | 22 (12.4%) | 16 (12.7%) | 6 (11.8%) | ||
| IIIB | 14 (7.9%) | 12 (9.5%) | 2 (3.9%) | ||
| IIIC | 7 (4%) | 4 (3.2%) | 3 (5.9%) | ||
| IVA | 9 (5.1%) | 5 (4%) | 4 (7.8%) | ||
| IVB | 2 (1.1%) | 2 (1.6%) | - | ||
| Lymph node (LN) status | Not involved | 127 (71.8%) | 94 (74.6%) | 33 (64.7%) | 0.255 |
| 1-2 LN with <5 mm | 21 (11.9%) | 13 (10.3%) | 8 (15.7%) | ||
| >5 mm or >2 LNs or extra capsular infiltration | 25 (14.1%) | 19 (15.1%) | 6 (11.8%) | ||
| No staging | 4 (2.3%) | 0 (0%) | 4 (7.8%) | ||
| Further therapy (Radio-/radiochemotherapy) | 32 (18.1%) | 23 (18.3%) | 9 (17.6%) | ||
Figure 3Kaplan-Meier curves of progression-free (a) and overall survival in both groups (b).